- Home
- NRIX vs TYG Comparison
NRIX vs TYG Comparison
Compare NRIX & TYG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- TYG
- Stock Information
- Founded
- NRIX 2009
- TYG 2003
- Country
- NRIX United States
- TYG United States
- Employees
- NRIX N/A
- TYG N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- TYG Investment Managers
- Sector
- NRIX Health Care
- TYG Finance
- Exchange
- NRIX Nasdaq
- TYG Nasdaq
- Market Cap
- NRIX 728.6M
- TYG 728.7M
- IPO Year
- NRIX 2020
- TYG N/A
- Fundamental
- Price
- NRIX $10.69
- TYG $43.77
- Analyst Decision
- NRIX Strong Buy
- TYG
- Analyst Count
- NRIX 14
- TYG 0
- Target Price
- NRIX $29.07
- TYG N/A
- AVG Volume (30 Days)
- NRIX 1.2M
- TYG 56.0K
- Earning Date
- NRIX 10-09-2025
- TYG 01-01-0001
- Dividend Yield
- NRIX N/A
- TYG 10.01%
- EPS Growth
- NRIX N/A
- TYG N/A
- EPS
- NRIX N/A
- TYG 5.19
- Revenue
- NRIX $88,381,000.00
- TYG $18,090,640.00
- Revenue This Year
- NRIX $74.59
- TYG N/A
- Revenue Next Year
- NRIX N/A
- TYG N/A
- P/E Ratio
- NRIX N/A
- TYG $8.38
- Revenue Growth
- NRIX 41.86
- TYG 32.84
- 52 Week Low
- NRIX $8.18
- TYG $33.73
- 52 Week High
- NRIX $29.56
- TYG $48.76
- Technical
- Relative Strength Index (RSI)
- NRIX 63.25
- TYG 63.98
- Support Level
- NRIX $8.20
- TYG $42.85
- Resistance Level
- NRIX $10.23
- TYG $43.43
- Average True Range (ATR)
- NRIX 0.50
- TYG 0.39
- MACD
- NRIX 0.27
- TYG 0.12
- Stochastic Oscillator
- NRIX 99.80
- TYG 89.56
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About TYG Tortoise Energy Infrastructure Corporation
Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.